Testing an experimental treatment for moderate to severe Crohn's disease
Treatments studied
Part of Digestive system, Pain clinical trials.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You weigh at least 40 kg (about 88 lbs).
- You have been diagnosed with Crohn's disease for at least one year, with active inflammation confirmed by a colonoscopy.
- Your Crohn's disease is moderate to severe and has not improved after trying two or more advanced treatments like TNF-inhibitors, IL-12/23 inhibitors, anti-integrins, or JAK inhibitors.
- You are not currently taking more than 20 mg of prednisone (or equivalent) per day, or more than 9 mg of budesonide per day.
- You do not have any uncontrolled infections, HIV, active hepatitis B or C, or untreated tuberculosis.
- You do not have certain Crohn's complications like active fistulas, abscesses, strictures that cannot be dilated, or a prior organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.